IL1B and type 2 diabetes mellitus: Cytokine signaling blockade (ex, IL-1β inhibitors) and targeted dampening of microglial activation by specific inhibitors, CSF1R blockers, have shown efficacy in controlling the inflammation and thus serving some therapeutic effects for AD and T2D patients (Zhou et al. 2024).